Healthleap Lands $38M for AI That Flags Undiagnosed Patients

Healthleap, a startup founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, has pulled in $38 million across two rounds: an $8 million seed co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. TechCrunch reports that the company originally built a clinical nutrition tool and has since widened the aperture to malnutrition, delirium, aspiration pneumonia, pressure ulcers, and congestive heart failure readmission risk.

The product plugs into hospital EHRs and uses language models to pull clinical indicators out of physician notes, specifically phrases like "poor appetite, recent weight loss, muscle loss, trouble swallowing," then combines those with labs, vital signs, and medications to score which patients may have an undiagnosed condition worth a second look.

Healthleap says it runs in more than 50 hospitals, including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. On revenue, Josiah Meyer told TechCrunch, "Revenue has grown more than 10x over the same period." Contracts are outcome-based, and the company's pitch leans hard on a single number: "every customer has seen a 5x hard ROI or more, in some cases over 20x." At the Hospital of the University of Pennsylvania, Healthleap says its malnutrition program generated $23.8 million in annualized financial impact.

That ROI claim is the company's own, and the TechCrunch write-up does not break out how Penn's $23.8 million was measured or audited. Next on the roadmap: expanding to more than 40 conditions and pushing into outpatient and home care markets.

This is one of 64 healthcare AI stories we've tracked in the last 90 days, and the third funding alert we're logging today.